Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis
American Journal of Hematology, 06/15/2012
Sarvaiya PJ et al. – The results identify c–Myb as a potential therapeutic target in pre–B–Acute lymphoblastic leukemia (ALL) and suggest that suppression of c–Myb levels or activity, in combination with currently used therapies and/or dose reduction, may lead to a decrease in toxicity and an increase in patient survival rates. Because c–Myb is aberrantly expressed in several other malignancies, targeting c–Myb will have broad clinical applications.